Member Info for Chelsea11

Thanks Chester, I was sat here wondering about the significance of the mention of “follow up data from the BioNTech mRNA vaccine”

Surely has to be Scancell relevant, for them to have included that line.

Date-wise, touch & go whether I will be able to top up my Stocks & Shares ISA in the new tax year, before the volcano sized eruption of good news 😉

That was code from Chester for - you wouldn't wanna be out of this over the Bank Holiday weekend.

Or could be just trying to squeeze full value for money from that RNS package they purchased.

Another half a dozen blockbusters next week would be good.

Suspect housekeeping only. Tidy up job.

Happy to be proven wrong.

WTP - I am expecting a standalone RNS based on past form.

You mean this?

https://www.abstractsonline.com/pp8/#!/20272/presentation/11402

(You may need to copy paste)

How about substitute Cheap Buy-OUT, for Cheap Buy-IN 😁

Roll on the new Tax Year, as with the short-medium term future looking so bright here, it would be rude not to take advantage of that opportunity. IMO of course.

Folk who go by the name of Traders would be my best guess 😂

Great stuff and news that makes a complete mockery of this mornings bellyaching

In my opinion, recent communications have been more informative and commercially focussed.

You just need to actually read them, to know what to expect and by when.

No data is expected anyway. Q1 was completion of recruitment target.

As we know from RNS, Scancell have recently attended Oxford Biologics in London. Worth pointing out I think that there is a sister conference in October, in San Diego and I suspect that might also be a Scancell road trip. Perhaps not in a limousine though 😂

https://oxfordglobal.com/biologics/events/biologics-us-2024

HAGW (Q1 comes to an end one week tomorrow - a recruitment and data published milestone)

I’m with Chester. Block out all the tiresome bleating from some quarters and take advantage of the new ISA year, as that aligns nicely to 2024/25 news / data delivery expectations published by the Company.

Can’t see any commas in the wrong place though Ray 😂

Attempting to make comparisons in that way is in my opinion, utterly pointless. There are way, way too many variables.

We know the timeline here to expect data (assuming no delays) and it is that, that will ultimately drive any blue chip pharma interest / deal.

A reminder of the PRESENTATION later today.

https://oxfordglobal.com/biologics/events/biologics-2024#speakers

The Agenda is available for download at the link. Best of luck to the Scancell scientists.

Next stop Barcelona.

HAGW

Green453 - the Scancell lab folk look a bit like this, except they’re not making steam irons.

https://www.youtube.com/watch?v=2r7XfhTKRMw

Suspect many of us thought his delivery & support during the Results Presentation was excellent.

Seems the Scancell management think the same and have moved to strengthen the board. IMO.

Violin - I don’t think anyone should be using the FARN product BEXMAB as a “potential blueprint” for SCIB. For a start, FARN have only recently had their pants pulled down due to the need to disclose events of default on debt obligations to their lender. Saying that Scancell are better funded is somewhat of an understatement and will clearly have an impact on development & commercialisation.

So personally, I don’t see any correlation and really hope none exists.